TWI233361B - Methods of preventing UVB-induced skin damage - Google Patents

Methods of preventing UVB-induced skin damage Download PDF

Info

Publication number
TWI233361B
TWI233361B TW091107218A TW91107218A TWI233361B TW I233361 B TWI233361 B TW I233361B TW 091107218 A TW091107218 A TW 091107218A TW 91107218 A TW91107218 A TW 91107218A TW I233361 B TWI233361 B TW I233361B
Authority
TW
Taiwan
Prior art keywords
tsp
skin
composition
cells
cell
Prior art date
Application number
TW091107218A
Other languages
English (en)
Chinese (zh)
Inventor
Michael J Detmar
Kiichiro Yano
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of TWI233361B publication Critical patent/TWI233361B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW091107218A 2001-04-13 2002-04-10 Methods of preventing UVB-induced skin damage TWI233361B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28387401P 2001-04-13 2001-04-13

Publications (1)

Publication Number Publication Date
TWI233361B true TWI233361B (en) 2005-06-01

Family

ID=23087934

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091107218A TWI233361B (en) 2001-04-13 2002-04-10 Methods of preventing UVB-induced skin damage

Country Status (8)

Country Link
US (1) US6712617B2 (OSRAM)
EP (1) EP1377253A4 (OSRAM)
JP (1) JP2004526758A (OSRAM)
KR (2) KR20080108366A (OSRAM)
CN (1) CN100340287C (OSRAM)
CA (1) CA2446093A1 (OSRAM)
TW (1) TWI233361B (OSRAM)
WO (1) WO2002083088A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266706A1 (en) * 2002-11-05 2004-12-30 Muthiah Manoharan Cross-linked oligomeric compounds and their use in gene modulation
TWI312681B (en) * 2001-02-01 2009-08-01 Novel physiologically active substance
TWI334866B (en) * 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
US7238370B2 (en) * 2002-06-14 2007-07-03 Rosenberg E William Method and composition to prevent and treat photoaging of skin
JP5122060B2 (ja) * 2002-06-25 2013-01-16 株式会社 資生堂 抗老化剤
EP1541570A4 (en) * 2002-07-31 2008-05-21 Mercian Corp NEW PHYSIOLOGICALLY EFFECTIVE SUBSTANCE
WO2004011661A1 (ja) * 2002-07-31 2004-02-05 Mercian Corporation 新規生理活性物質
AU2003282683A1 (en) 2002-10-04 2004-05-04 Photokinetix Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
DE10254214A1 (de) * 2002-11-20 2004-06-09 Beiersdorf Ag Oligoribonukleotide zur Behandlung von degenerativen Hauterscheinungen durch RNA-Interferenz
NZ540103A (en) * 2002-11-29 2007-05-31 Mercian Corp Process for producing macrolide compound
AU2006246425B2 (en) * 2003-11-06 2012-03-22 Genencor International, Inc. Personal care compositions and methods for their use
WO2005097187A2 (en) * 2004-04-01 2005-10-20 The General Hospital Corporation Methods of preventing uvb-induced skin damage
US20050276762A1 (en) * 2004-06-15 2005-12-15 Tapas Das Topical compositions containing 5'-adenosine-diphosphate ribose
WO2006042114A1 (en) * 2004-10-06 2006-04-20 Cook, Inc. Emboli capturing device having a coil and method for capturing emboli
US7831890B2 (en) 2004-10-12 2010-11-09 Aware, Inc. Resource sharing in a telecommunications environment
EP2561883A3 (en) * 2005-09-16 2013-04-17 Shiseido Company, Ltd. Novel vascular endothelial growth factor expression inhibitors
ATE476986T1 (de) 2006-01-18 2010-08-15 Gen Hospital Corp Verfahren zur steigerung der lymphatischen funktion
US8335956B2 (en) 2006-04-12 2012-12-18 Tq Delta, Llc Packet retransmission and memory sharing
WO2008005533A2 (en) * 2006-07-06 2008-01-10 Aaron Thomas Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
AU2007285215A1 (en) * 2006-08-14 2008-02-21 Eisai R & D Management Co., Ltd. Stable lyophilized preparation
MX2009008068A (es) * 2007-01-29 2009-11-18 Eisai R&D Man Co Ltd Compuesto macrolido en forma solida, proceso para su preparacion y composicion farmaceutica que lo contiene.
KR20100065190A (ko) 2007-09-14 2010-06-15 닛토덴코 가부시키가이샤 약물 담체
US9132202B2 (en) 2009-07-17 2015-09-15 Aaron T. Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
ES2687780T3 (es) 2009-09-30 2018-10-29 Shiseido Company, Ltd. Inhibidor de la actividad heparanasa
US12358963B2 (en) 2019-12-24 2025-07-15 Juvena Therapeutics, Inc. Regenerative polypeptides and uses thereof
WO2021133858A1 (en) * 2019-12-24 2021-07-01 Juvena Therapeutics, Inc. Heparin-associated polypeptides and uses thereof
CA3223707A1 (en) 2021-06-21 2022-12-29 Hanadie Yousef Regenerative polypeptides and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025334A (en) * 1994-04-28 2000-02-15 Les Laboratoires Aeterna Inc. Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof
US6372234B1 (en) 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
CN1084595C (zh) * 1997-05-27 2002-05-15 塞姆柏奥希斯遗传学公司 油体的用途
WO1999026649A1 (en) * 1997-11-25 1999-06-03 Cornell Research Foundation, Inc. Methods and compositions for inhibiting hiv infectivity and blocking chemokine activity
AU766098B2 (en) 1999-03-31 2003-10-09 General Hospital Corporation, The Thrombospondin-2 and uses thereof
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis

Also Published As

Publication number Publication date
US20030008821A1 (en) 2003-01-09
KR20040021598A (ko) 2004-03-10
KR20080108366A (ko) 2008-12-12
CN100340287C (zh) 2007-10-03
JP2004526758A (ja) 2004-09-02
CN1512868A (zh) 2004-07-14
EP1377253A4 (en) 2008-09-03
EP1377253A1 (en) 2004-01-07
WO2002083088A1 (en) 2002-10-24
US6712617B2 (en) 2004-03-30
CA2446093A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
US6712617B2 (en) Methods of preventing UVB-induced skin damage
DE69821011T2 (de) Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen
Harrington et al. Influence of tumour size on uptake of111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model
ES2525476T3 (es) Derivados de alfa-MSH para el tratamiento de fotodermatosis
Wasterlain et al. Felbamate reduces hypoxic-ischemic brain damage in vivo
KR20080108530A (ko) 신경 쓰레드 단백질 기초 펩티드를 사용하여 암 위험 또는 발병을 예방 또는 감소시키는 방법
Tognetti et al. UVA‐1 phototherapy as adjuvant treatment for eosinophilic fasciitis: in vitro and in vivo functional characterization
JP2006521405A (ja) 発作回復におけるエリトロポイエチンの使用
US20050276765A1 (en) Preventing skin damage
Wang et al. Effects of delayed treatment with transforming growth factor-β soluble receptor in a three-dose bleomycin model of lung fibrosis in hamsters
EP1131087B1 (en) Methods of alleviating cancer symptoms
US10857199B2 (en) Compounds and methods for increasing hair growth
US8133491B1 (en) Compositions and methods for treatment of hyperplastic disorders
US20230364192A1 (en) Modulation of beta cell regeneration through gpr75 signaling
CN118806788A (zh) 活性氧在预防和/或治疗纤维化及与纤维化明确相关的疾病中的用途
US20210213137A1 (en) Compositions to treat ultraviolet (uv)-induced skin injury
WO2021188802A1 (en) Molecular transport system to the central nervous system
Desai et al. Noncanonical Nf-κB Activation by Icariin-Triggered CEBP-β/G-CSF Axis Confers Neuroprotection in Ischemic Optic Neuropathy
Esteban Pyrrole-imidazole polyamide-H promotes anti-inflammation during the acute phase of spinal cord injury
AU2002254588A1 (en) Methods of Preventing UVB-Induced Skin Damage
JP2022532306A (ja) フェキサポチドトリフルタートを用いた下部尿路症状の治療効果を高める方法
HK1066173A (en) Methods of alleviating cancer symtoms
CN111588854A (zh) Trf2或其上调剂在制备治疗肌肉疾病的药物中的应用
Sinn et al. Albumin-Based Drug Delivery as Novel
WO2017075661A1 (en) Methods and compositions for treating cns injury

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent